Drugs Approved for Renal Cell Cancer (RCC)
- Afinitor (Everolimus)
- Afinitor Disperz (Everolimus)
- Aldesleukin
- Alymsys (Bevacizumab)
- Avastin (Bevacizumab)
- Avelumab
- Axitinib
- Bavencio (Avelumab)
- Belzutifan
- Bevacizumab
- Cabometyx (Cabozantinib-S-Malate)
- Cabozantinib-S-Malate
- Everolimus
- Fotivda (Tivozanib Hydrochloride)
- IL-2 (Aldesleukin)
- Inlyta (Axitinib)
- Interleukin-2 (Aldesleukin)
- Ipilimumab
- Keytruda (Pembrolizumab)
- Lenvatinib Mesylate
- Lenvima (Lenvatinib Mesylate)
- Mvasi (Bevacizumab)
- Nexavar (Sorafenib Tosylate)
- Nivolumab
- Nivolumab and Hyaluronidase-nvhy
- Opdivo (Nivolumab)
- Opdivo Qvantig (Nivolumab and Hyaluronidase-nvhy)
- Pazopanib Hydrochloride
- Pembrolizumab
- Proleukin (Aldesleukin)
- Sorafenib Tosylate
- Sunitinib Malate
- Sutent (Sunitinib Malate)
- Temsirolimus
- Tivozanib Hydrochloride
- Torisel (Temsirolimus)
- Votrient (Pazopanib Hydrochloride)
- Welireg (Belzutifan)
- Yervoy (Ipilimumab)
- Zirabev (Bevacizumab)
Drugs Approved for Upper Tract Urothelial Cancer (UTUC)
Drugs Approved for Wilms Tumor and other Childhood Kidney Cancers